ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE', a zinc gluconate glycine product. COLD-EEZE' family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania....
+See More2018-11-29 11:33:00 Thursday ET
A congressional division between Democrats and Republicans can cause ripple effects on Trump economic reforms. As Democrats have successfully flipped the Ho
2025-06-21 10:25:00 Saturday ET
Former New York Times science author and Harvard psychologist Daniel Goleman explains why emotional intelligence can serve as a more important critical succ
2020-07-19 09:25:00 Sunday ET
Senior business leaders can learn much from the lean production system with iterative continuous improvements at Toyota. Takehiko Harada (2015)
2019-04-30 07:15:00 Tuesday ET
Through our AYA fintech network platform, we share numerous insightful posts on personal finance, stock investment, and wealth management. Our AYA finte
2018-03-21 06:32:00 Wednesday ET
Fed Chair Jerome Powell increases the neutral interest rate to a range of 1.5% to 1.75% in his debut post-FOMC press conference. The Federal Reserve raises
2019-09-11 09:31:00 Wednesday ET
Central banks in India, Thailand, and New Zealand lower their interest rates in a defensive response to the Federal Reserve recent rate cut. The central ban